Annual changes to the NASDAQ Biotechnology Index
Last week Nasdaq announced the results of the annual re-ranking of the NASDAQ Biotechnology Index, which
went into effect prior to today's market open.
The following 21 securities have been added to the Index:
Exchange
SYMBOL
COMPANY NAME
Nasdaq
AIMT
Aimmune Therapeutics, Inc.
Nasdaq
ARLZ
Aralez Pharmaceuticals Inc.
Nasdaq
AVXS
AveXis, Inc.
Nasdaq
BGNE
BeiGene, Ltd.
Nasdaq
BOLD
Audentes Therapeutics
Nasdaq
CLCD
CoLucid Pharmaceuticals
Nasdaq
CLSD
Clearside Biomedical, Inc.
Nasdaq
CYTK
Cytokinetics, Incorporated
Nasdaq
EDIT
Editas Medicine, Inc.
Nasdaq
GBT
Global Blood Therapeutics
Nasdaq
ITCI
Intra-Cellular Therapies
Nasdaq
LOXO
Loxo Oncology, Inc.
Nasdaq
MNOV
Medicinova Inc
Nasdaq
NERV
Minerva Neurosciences
Nasdaq
NH
NantHealth, Inc.
Nasdaq
NTLA
Intellia Therapeutics, Inc.
Nasdaq
NVCR
NovoCure Limited
Nasdaq
ONVO
Organovo Holdings Inc
Nasdaq
OPK
OPKO Health, Inc.
Nasdaq
PRTK
Paratek Pharmaceuticals, Inc.
Nasdaq
RGNX
REGENXBIO Inc.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
As a result of the re-ranking, the following 37 securities will be removed from the Index:
Exchange
SYMBOL
COMPANY NAME
Nasdaq
ADHD
Alcobra Ltd.
Nasdaq
ADVM
Adverum Biotechnologies, Inc.
Nasdaq
AFMD
Affimed N.V.
Nasdaq
AGTC
Applied Genetic Technologies Corporation
Nasdaq
ANTH
Anthera Pharmaceuticals, Inc.
Nasdaq
CARA
Cara Therapeutics, Inc.
Nasdaq
CASC
Cascadian Therapeutics, Inc.
Nasdaq
CHMA
Chiasma, Inc.
Nasdaq
CMRX
Chimerix, Inc.
Nasdaq
CNCE
Concert Pharmaceuticals, Inc.
Nasdaq
CXRX
Concordia International Corp.
Nasdaq
DNAI
ProNAi Therapeutics, Inc.
Nasdaq
DRNA
Dicerna Pharmaceuticals, Inc.
Nasdaq
DRRX
DURECT Corporation
Nasdaq
ECYT
Endocyte, Inc.
Nasdaq
EGLT
Egalet Corporation
Nasdaq
FLKS
Flex Pharma, Inc.
Nasdaq
IMDZ
Immune Design Corp.
Nasdaq
IMGN
ImmunoGen, Inc.
Nasdaq
INFI
Infinity Pharmaceuticals, Inc.
Nasdaq
ITEK
Inotek Pharmaceuticals Corporation
Nasdaq
KMPH
KemPharm, Inc.
Nasdaq
LIFE
aTyr Pharma, Inc.
Nasdaq
MNKD
MannKind Corporation
Nasdaq
NDRM
NeuroDerm Ltd.
Nasdaq
NEOS
Neos Therapeutics, Inc.
Nasdaq
OCUL
Ocular Therapeutix, Inc.
Nasdaq
OREX
Orexigen Therapeutics, Inc.
Nasdaq
OSIR
Osiris Therapeutics, Inc.
Nasdaq
OVAS
OvaScience Inc.
Nasdaq
QURE
uniQure N.V.
Nasdaq
RGLS
Regulus Therapeutics Inc.
Nasdaq
SCLN
SciClone Pharmaceuticals, Inc.
Nasdaq
TKAI
Tokai Pharmaceuticals, Inc.
Nasdaq
TTPH
Tetraphase Pharmaceuticals, Inc.
Nasdaq
VTL
Vital Therapies, Inc.
Nasdaq
ZFGN
Zafgen, Inc.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.